Department of Pathology and Laboratory Medicine, University of Rochester, Rochester, NY, USA.
Department of Laboratory Medicine and Pathology, University of Minnesota, 420 Washington Ave SE, Minneapolis, MN, 55455, USA.
Diabetologia. 2019 May;62(5):822-834. doi: 10.1007/s00125-019-4834-0. Epub 2019 Mar 1.
AIMS/HYPOTHESIS: We previously reported that exposure to antibodies neutralising serpin B13, a protease inhibitor expressed in exocrine pancreatic ducts, promotes beta cell proliferation, underscoring the importance of a functional relationship between exocrine and endocrine pancreas. The aim of the present study was to identify the molecular events that link inhibition of serpin B13 to islet cell proliferation.
We used an in vitro culture system consisting of isolated pancreatic islets, an extract of pancreatic ductal epithelium and a monoclonal antibody (mAb) to serpin B13 or IgG isotype control. In vivo studies involved treatment of mice with these mAbs.
The catalytic activity of cathepsin L (CatL), a cysteine protease target of serpin B13, was augmented in the pancreas of mice injected with serpin B13 mAb. Furthermore, the addition of serpin B13 mAb to the islets, together with the pancreatic ductal epithelium lysate, caused CatL-dependent cleavage of E-cadherin and concomitant upregulation of REG genes, ultimately leading to beta cell proliferation. Direct blockade of E-cadherin with mAb also markedly enhanced REG gene induction, while chemical inhibition of β-catenin, a binding target of E-cadherin, prevented the serpin B13 mAb-induced upregulation of REG genes.
CONCLUSIONS/INTERPRETATION: Our work implicates the CatL-E-cadherin-REG pathway in the regulation of islet cell proliferation in response to signals generated in exocrine pancreatic tissue and demonstrates that protease activity may promote adaptive changes in the islets.
Microarray data that support the findings of this study have been deposited in Gene Expression Omnibus (GEO) with the accession no. GSE125151.
目的/假设:我们之前报道过,暴露于能够中和丝氨酸蛋白酶抑制剂 B13(一种在外分泌胰腺导管中表达的蛋白酶抑制剂)的抗体,会促进β细胞增殖,这突显了外分泌和内分泌胰腺之间存在功能关系的重要性。本研究的目的是确定将丝氨酸蛋白酶抑制剂 B13 的抑制与胰岛细胞增殖联系起来的分子事件。
我们使用了一种体外培养系统,该系统由分离的胰岛、胰腺导管上皮提取物和针对丝氨酸蛋白酶抑制剂 B13 的单克隆抗体(mAb)或 IgG 同型对照组成。体内研究涉及用这些 mAb 治疗小鼠。
丝氨酸蛋白酶抑制剂 B13 的催化活性CatL(丝氨酸蛋白酶抑制剂 B13 的靶标)在注射丝氨酸蛋白酶抑制剂 B13 mAb 的小鼠胰腺中增强。此外,将丝氨酸蛋白酶抑制剂 B13 mAb 与胰岛一起添加到胰腺导管上皮裂解物中,导致 CatL 依赖性切割 E-钙黏蛋白,并伴随 REG 基因的上调,最终导致β细胞增殖。用 mAb 直接阻断 E-钙黏蛋白也显著增强了 REG 基因的诱导,而β-连环蛋白(E-钙黏蛋白的结合靶标)的化学抑制则阻止了丝氨酸蛋白酶抑制剂 B13 mAb 诱导的 REG 基因上调。
结论/解释:我们的工作表明,CatL-E-钙黏蛋白-REG 途径参与了对外分泌胰腺组织产生的信号的胰岛细胞增殖的调节,并表明蛋白酶活性可能促进胰岛的适应性变化。
支持本研究发现的微阵列数据已被存入基因表达综合数据库(GEO),注册号为 GSE125151。